
Sign up to save your podcasts
Or


The pharmaceutical industry is making some bold constitutional arguments in its attempts to overturn a new law allowing Medicare to negotiate directly with drug makers on prices.
The industry says the law, part of the Biden administration's Inflation Reduction Act, violates the Fifth, Eighth, and even First Amendment rights of companies like Merck, Johnson & Johnson, and AstraZeneca, among others.
On this episode of our weekly podcast, On The Merits, Celine Castronuovo and David Schultz look into why the drug makers are waging this uphill legal battle against Medicare negotiations and whether they'll ultimately succeed.
Do you have feedback on this episode of On The Merits? Give us a call and leave a voicemail at 703-341-3690.
By Bloomberg Law4.1
3232 ratings
The pharmaceutical industry is making some bold constitutional arguments in its attempts to overturn a new law allowing Medicare to negotiate directly with drug makers on prices.
The industry says the law, part of the Biden administration's Inflation Reduction Act, violates the Fifth, Eighth, and even First Amendment rights of companies like Merck, Johnson & Johnson, and AstraZeneca, among others.
On this episode of our weekly podcast, On The Merits, Celine Castronuovo and David Schultz look into why the drug makers are waging this uphill legal battle against Medicare negotiations and whether they'll ultimately succeed.
Do you have feedback on this episode of On The Merits? Give us a call and leave a voicemail at 703-341-3690.

3,549 Listeners

1,971 Listeners

383 Listeners

488 Listeners

9,558 Listeners

669 Listeners

156 Listeners

6,310 Listeners

113 Listeners

2,336 Listeners

32,338 Listeners

173 Listeners

6,072 Listeners

5,554 Listeners

16,132 Listeners

744 Listeners

155 Listeners

394 Listeners